Valneva Austria
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (28)
A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children
Started: 2/6/2026
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
Started: 4/2/2021
A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
Started: 4/10/2024
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
Started: 2/22/2021
Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years
Started: 8/9/2021
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
Started: 9/17/2020
COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222
Started: 4/26/2021
Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population
Started: 3/1/2010
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
Started: 1/1/2010
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
Started: 10/1/2010
Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
Started: 9/1/2008
Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country
Started: 12/1/2010
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
Started: 12/18/2023
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
Started: 5/9/2022
Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701
Started: 6/4/2018
Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study
Started: 12/1/2014
Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43
Started: 3/1/2012
Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients
Started: 12/1/2008
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
Started: 3/25/2024
Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
Started: 12/16/2020
Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers
Started: 3/5/2018
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
Started: 2/24/2018
An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84
Started: 12/1/2010
Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination
Started: 6/1/2012
Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47
Started: 3/1/2009
Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers
Started: 9/1/2008
This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population
Started: 6/1/2010